3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Specimen Handling
14
Magnetic Resonance Spectroscopy
14
Doxorubicin
11
Cyclophosphamide
11
Biopsy
9
Radiation
8
atezolizumab
7
Temozolomide
7
X-Rays
6
Vincristine
6
Nivolumab
6
Etoposide
6
Bevacizumab
6
liposomal doxorubicin
5
fludarabine
5
cabozantinib
5
Sirolimus
5
Radiotherapy
5
Phantoms, Imaging
5
Irinotecan
5
Immunoglobulin G
5
Ifosfamide
5
Disulfides
5
pembrolizumab
4
Nuclear Medicine Department, Hospital
4
temsirolimus
3
palbociclib
3
olaparib
3
fludarabine phosphate
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Counseling
×
Sarcoma
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled